CaryHealth Clair vs OpenEvidence (2026)
A small bounded reference product against the most scrutinised one in the category. Clair answers from a named corpus of public drug, trial and guideline sources with every response linked back to its references, and it describes its retrieval technique more concretely than several better resourced peers. OpenEvidence reaches current primary literature through partnerships with major journals and a systematic review publisher, is free to verified United States clinicians, and carries eleven independent studies evaluating it, which is more external scrutiny than anything else here. For most clinicians OpenEvidence is the stronger product and its advertising funded model is the thing to weigh. Clair's value is that its corpus is bounded and stated, which makes what it does not cover knowable.
- The corpus is bounded and named over public drug, trial and guideline sources, with every response linked back to its references and source routing described.
- It names more technique than several better graded peers, describing retrieval and grounding rather than gesturing at reasoning.
- A published interface means another product can embed the reference layer rather than adopting the application.
- The independent literature is the deepest in this category, with a systematic review identifying eleven studies evaluating it across two years.
- Named partnerships with major journals and a systematic review publisher supply current primary literature rather than a static corpus.
- It is free to verified United States clinicians with enterprise record system embedding documented at named health systems.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. CaryHealth Clair and OpenEvidence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | CaryHealth Clair | OpenEvidence |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Founded | Not recorded | 2021 |
| Headquarters | Washington, District of Columbia | Miami, Florida |
| Website | cary.health | openevidence.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards CaryHealth Clair its top capability grade on AI Centrality. Set against OpenEvidence, CaryHealth Clair does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Its thinnest published disclosure sits on Clinical and Operational Evidence, AI Governance and Bias Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards OpenEvidence its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against CaryHealth Clair, OpenEvidence grades higher on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose CaryHealth Clair or OpenEvidence?
The AI Health Index grades OpenEvidence higher than CaryHealth Clair on every axis that separates them, several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and AI Safety and PHI Stewardship. CaryHealth Clair does not grade higher on any scored axis.
Where do CaryHealth Clair and OpenEvidence differ most?
The widest separation the AI Health Index records between CaryHealth Clair and OpenEvidence is on Clinical and Operational Evidence, where CaryHealth Clair grades D and OpenEvidence grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do CaryHealth Clair and OpenEvidence grade the same?
The AI Health Index grades CaryHealth Clair and OpenEvidence the same on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have CaryHealth Clair and OpenEvidence not disclosed?
At the last review, at least one of CaryHealth Clair and OpenEvidence published thin or absent detail on Clinical and Operational Evidence, AI Governance and Bias Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
OpenEvidence is funded by pharmaceutical and medical device advertising displayed alongside clinical answers, governed by a published advertising policy that is the artifact to read before accepting the arrangement in a clinical setting. Clair publishes no security certification, accuracy measurement or error rate, and its commercial disclosure takes a distinctive form that a buyer should read carefully rather than assume. Neither publishes a mechanism for detecting a superseded source, which is the failure mode of any curated corpus.